Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CARL ALLEN and ERIN PECKHAM-GREGORY.
CARL ALLEN
Connection Strength
2.088
ERIN PECKHAM-GREGORY
  1. A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood. 2017 11 16; 130(20):2229-2232.
    View in: PubMed
    Score: 0.540
  2. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 Jul 10; 146(2):206-218.
    View in: PubMed
    Score: 0.232
  3. Genomic Alterations in Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2025 06; 39(3):491-511.
    View in: PubMed
    Score: 0.227
  4. Role of non-chromosomal birth defects on the risk of developing childhood Hodgkin lymphoma: A Children's Oncology Group study. Pediatr Blood Cancer. 2024 Mar; 71(3):e30822.
    View in: PubMed
    Score: 0.208
  5. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.140
  6. Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.128
  7. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.074
  8. Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis. Pediatr Blood Cancer. 2026 Jul 27; e70525.
    View in: PubMed
    Score: 0.062
  9. Genome-wide association study identifies and validates genetic variation in the RIG-I/MAVS signaling pathway associated with HIV-related Kaposi sarcoma in children and adults. Front Oncol. 2026; 16:1796311.
    View in: PubMed
    Score: 0.062
  10. Relapse patterns among children and adolescents with Kaposi sarcoma in Malawi. Pediatr Hematol Oncol. 2025 Aug; 42(5):276-286.
    View in: PubMed
    Score: 0.058
  11. Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures. Cancer. 2024 Jul 15; 130(14):2416-2439.
    View in: PubMed
    Score: 0.053
  12. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.053
  13. Pediatric HIV+ Kaposi sarcoma exhibits clinical, virological, and molecular features different from the adult disease. JCI Insight. 2023 11 22; 8(22).
    View in: PubMed
    Score: 0.052
  14. Long-term outcomes for children and adolescents with Kaposi sarcoma. HIV Med. 2022 02; 23(2):197-203.
    View in: PubMed
    Score: 0.045
  15. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.044
  16. Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome-like Clinical Presentation in Human Immunodeficiency Virus-infected Children in Malawi. Clin Infect Dis. 2019 11 13; 69(11):2022-2025.
    View in: PubMed
    Score: 0.039
  17. Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infect Agent Cancer. 2018; 13:33.
    View in: PubMed
    Score: 0.036
  18. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.